Loading...
•
Dec 31, 2024
OraSure Q4 2024 Earnings Report
OraSure Technologies, Inc. reported its financial results for the fourth quarter ended December 31, 2024.
Key Takeaways
OraSure Technologies reported a 51% decrease in total net revenues for Q4 2024, primarily due to a significant decline in COVID-19 revenues. Despite this, core revenues showed a 10% year-over-year growth, indicating a gradual recovery in key end markets and diversification efforts.
Total net revenues for Q4 2024 decreased 51% to $37.4 million, primarily driven by the decline in COVID-19 revenues.
Core revenues (excluding COVID-19 and Molecular Services) increased 10% year-over-year to $36.5 million in Q4 2024.
The company reported a GAAP operating loss of $12.4 million in Q4 2024, compared to an operating income of $3.9 million in Q4 2023.
Cash and cash equivalents stood at $267.8 million as of December 31, 2024, with $5.0 million deployed for the acquisition of Sherlock Biosciences during the quarter.
Revenue by Segment
Forward Guidance
OraSure Technologies is guiding for Q1 2025 revenues between $27.5 million and $31.5 million, with core revenues expected to be $27 million to $31 million, including approximately $1 million from Risk Assessment testing revenues. COVID-19 revenues are projected to be around $0.5 million.
Positive Outlook
- Anticipated continued growth in core revenues, reflecting ongoing diversification and recovery in key markets.
- Strategic acquisition of Sherlock Biosciences expected to expand innovation pipeline with an advanced molecular platform.
- FDA approval for OraQuick® HIV Self-Test labeling change to include adolescents, broadening access to testing.
- Award received for the development of a Marburg Virus Disease rapid antigen test, indicating new revenue streams and public health contributions.
- Continued support for Risk Assessment customers while winding down remaining inventory, streamlining operations.
Challenges Ahead
- Overall revenue guidance for Q1 2025 is lower than Q4 2024, primarily due to the continued decline in COVID-19 revenues.
- Elevated uncertainty related to government funding sources for some existing customers.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...